Following U.S. Stocks may claim a “BIG Change,” in the course of current trading session: Auspex Pharmaceuticals Inc (NASDAQ:ASPX), Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), Nike Inc (NYSE:NKE), E I Du Pont De Nemours And Co (NYSE:DD)

• Auspex Pharmaceuticals Inc (NASDAQ:ASPX), with shares inclined 41.80% is now trading at $100.54, hitting new 52-week high of $100.86. The Stock is active as 1.91M shares changed hands versus its average volume of 305,575.00 shares.

• Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), with shares raised 0.82% is now trading at $62.49. The Stock is active as 2.11M shares changed hands versus its average volume of 4.65M shares.

• Nike Inc (NYSE:NKE) with shares enhanced 1.23% is now trading at $101.12. The Stock is active as 506,989.00 shares changed hands versus its average volume of 4.08M shares.

• E I Du Pont De Nemours And Co (NYSE:DD) with shares picked up1.49% is now trading at $72.72. The Stock is active as 917,334.00 shares changed hands versus its average volume of 5.66M shares.

Latest NEWS regarding these Stocks are depicted underneath:

Auspex Pharmaceuticals, Inc. (NASDAQ:ASPX)

Auspex Pharmaceuticals, Inc. (ASPX), declared that data from the accomplished Phase 3 registration clinical trial evaluating the corporation’s investigational new drug SD-809 (AustedoTM) in chorea associated with Huntington’s disease has been accepted for presentation at the 67th American Academy of Neurology (AAN) Annual Meeting taking place April 18-25, 2015 in Washington, DC. The results will be presented by Samuel A. Frank, M.D., associate professor of neurology, Boston University School of Medicine and principal investigator for the study, known as First-HD.

Auspex Pharmaceuticals, Inc., a biopharmaceutical corporation, focuses on developing and commercializing novel medicines for the treatment of orphan diseases. The corporation’s lead product, Austedo (SD-809), is in final stages of development for the treatment of chorea associated with Huntington’s disease, a neurodegenerative movement disorder that influences cognition, behavior and movements. In addition, Auspex is investing in the broad potential of Austedo for the treatment of other movement disorders, counting tardive dyskinesia and tics associated with Tourette syndrome.

Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Today, Teva Pharmaceutical Industries Limited (TEVA), and Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), declared that they have reached a definitive merger contract under which Teva will commence a tender offer for all of the outstanding shares of Auspex at $101.00 per share in cash, representing total consideration of about $3.2 billion in enterprise value and about $3.5 billion in equity value. This transaction is predictable to enhance Teva’s proceed and earnings growth profile and strengthen its core central nervous system (CNS) franchise with the addition of Auspex’s portfolio of innovative medicines for people who live with movement disorders. The transaction has been unanimously approved by the Boards of Directors of both Teva and Auspex, and key shareholders of Auspex have reached contracts indicating their support for the transaction.

In 2014, Auspex stated positive results from its Phase 3 clinical trial for SD-809 in Huntington’s disease, with plans to submit a New Drug Application (NDA) for this indication by mid-2015. SD-809 has been granted orphan drug designation for the treatment of Huntington’s disease by the United States Food and Drug Administration (FDA), and Auspex anticipates regulatory approval and commercial launch for this indication in 2016 in the United States. Topline results for Auspex’s Phase 3 ARM-TD study of SD-809 as a potential treatment for tardive dyskinesia, a disorder for which there are no approved therapies, are also predictable in mid-2015. Other pipeline candidates comprise deuterated versions of pirfenidone for idiopathic pulmonary fibrosis and levodopa for Parkinson’s disease. Auspex has an additional 60 molecules in its patent portfolio.

Transaction Highlights:

• Excellent planned fit – strengthens Teva’s leadership position within CNS and expands presence into underserved movement disorder markets,
• Teva’s existing capabilities and infrastructure in CNS are predictable to accelerate the potential for SD-809 and Auspex’s additional pipeline assets,
• Near-term value creation – SD-809 for Huntington’s disease is predictable to be approved and launched commercially in 2016,
• Deep pipeline and proven deuterium chemistry technology supports multiple platforms for growth,
• SD-809 is presently in Phase 3 for tardive dyskinesia and Phase 1 for Tourette syndrome,
• SD-560 (deuterated pirfenidone) is presently in development for idiopathic pulmonary fibrosis,
• Additional candidates identified for deuterium chemistry platform that are aligned with Teva’s strategy,
• Enhances Teva’s mid to long-term proceed and earnings growth, profitability, and product diversity - predictable to be accretive to non-GAAP EPS startning in 2017 and meaningfully accretive thereafter, and diversifies Teva’s Specialty medicines product mix.

The attainment of Auspex is predictable to generate value and enhance Teva’s mid to long-term proceed and earnings growth profile. Teva anticipates the transaction to start contributing to proceeds in 2016 with the anticipated launch of SD-809 for Huntington’s disease and to be accretive to non-GAAP EPS starting in 2017 with minimal dilution to non-GAAP EPS in the second half of 2015 and 2016. The transaction is predictable to be funded with cash on hand and is not subject to any financing contingencies.

A conference call and a live webcast with slides will be hosted on Monday, March 30, 2015 to talk about the transaction.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, counting pain, in addition to a strong portfolio of respiratory products.

Nike, Inc. (NYSE:NKE)

Nike, Inc. (NKE), was upgraded to “outperform” from “neutral” at Baird, which called Nike reasonably valued for one of the highest quality large cap growth companies in the consumer discretionary sector. Valuation call, as the corporation can deliver consistent 15% annual earnings growth, Robert Baird said.

NIKE, Inc., together with its auxiliaries, designs, develops, markets, and sells athletic footwear, apparel, equipment, and accessories for men, women, and kids worldwide.

1. I. du Pont de Nemours and Company (NYSE:DD)

The board of directors of E. I. du Pont de Nemours and Company (DD), has approved changes to the corporate governance structure at The Chemours Corporation (“Chemours”), following discussions with a wide range of shareholders and further evaluation, counting with respect to the recent treatment of governance at spin-off companies in other situations. As formerly declared, DuPont plans to execute the separation of its Performance Chemicals Segment through a tax-free spin-off to shareholders to create Chemours. The corporate governance changes at Chemours comprise that:

• Chemours’ classified board structure will be presented to a shareholder vote at Chemours’ first Annual Meeting in 2016. If the classified structure is not approved by shareholders at that meeting, Chemours would right away declassify its Board such that all directors would be up for annual election starting with the 2017 Annual Meeting; and
• The ownership threshold for shareholders to call special meetings has been lowered to 25%.

1. I. du Pont de Nemours and Corporation operates as a science and technology based corporation worldwide. The corporation’s Agriculture segment offers corn hybrid, soybean, canola, sunflower, sorghum, inoculants, seed products, wheat, rice, herbicides, fungicides, and insecticides.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.